Trial Profile
A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Hanmi Pharmaceutical
- 14 Oct 2013 Status changed from active, no longer recruiting to completed, as reported in a Hanmi Pharmaceutical media release.
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 03 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.